Cargando…

XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance

BACKGROUND: DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Sitian, Wang, Xiao Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437682/
https://www.ncbi.nlm.nih.gov/pubmed/28526069
http://dx.doi.org/10.1186/s12885-017-3345-y
_version_ 1783237640182562816
author Yang, Sitian
Wang, Xiao Qi
author_facet Yang, Sitian
Wang, Xiao Qi
author_sort Yang, Sitian
collection PubMed
description BACKGROUND: DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC). METHODS: qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on patients with HCC treated with transarterial chemoembolization (TACE). RESULTS: Many conventional cancer chemotherapeutics induce DNA double-strand breaks (DSBs). HCC cells respond to these breaks by increasing their NHEJ activity, resulting in resistance. XLF-knockdown cells show an inhibition of NHEJ activity in both cell-free and live-cell assays as well as a high level of unrepaired cellular DSBs. These results indicate that XLF facilitates DNA end-joining and therefore promotes NHEJ activity in cancer cells. Consequently, knockdown of XLF significantly chemosensitized resistant cells both in vitro and in xenograft tumors. A low rate of XLF genomic alteration was found in patients with primary HCC, but XLF expression was induced after drug treatment. Clinically, a high level of XLF expression is significantly associated with advanced HCC and shorter overall survival. CONCLUSION: Chemotherapy-induced overexpression of XLF and XLF-mediated enhancements in NHEJ activity contribute to chemoresistance in HCC cells and patients with HCC. Targeting XLF to modulate DSB repair could enhance drug sensitivity and may be a therapeutically useful addition to conventional therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3345-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5437682
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54376822017-05-22 XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance Yang, Sitian Wang, Xiao Qi BMC Cancer Research Article BACKGROUND: DNA repair pathways are used by cancer cells to overcome many standard anticancer treatments, causing therapy resistance. Here, we investigated the role of XRCC4-like factor (XLF), a core member of the non-homologous end joining (NHEJ) repair pathway, in chemoresistance in hepatocellular carcinoma (HCC). METHODS: qRT-PCR analysis and western blotting were performed to detect expression levels of genes and proteins related to NHEJ. NHEJ repair capacity was assessed in vitro (cell-free) and in vivo by monitoring the activity of the NHEJ pathway. Cell viability and IC50 assays were used to measure sensitivity to drug therapy. A xenograft HCC model was used to develop methods of targeting XLF-induced chemosensitization. Clinicopathological analysis was conducted on patients with HCC treated with transarterial chemoembolization (TACE). RESULTS: Many conventional cancer chemotherapeutics induce DNA double-strand breaks (DSBs). HCC cells respond to these breaks by increasing their NHEJ activity, resulting in resistance. XLF-knockdown cells show an inhibition of NHEJ activity in both cell-free and live-cell assays as well as a high level of unrepaired cellular DSBs. These results indicate that XLF facilitates DNA end-joining and therefore promotes NHEJ activity in cancer cells. Consequently, knockdown of XLF significantly chemosensitized resistant cells both in vitro and in xenograft tumors. A low rate of XLF genomic alteration was found in patients with primary HCC, but XLF expression was induced after drug treatment. Clinically, a high level of XLF expression is significantly associated with advanced HCC and shorter overall survival. CONCLUSION: Chemotherapy-induced overexpression of XLF and XLF-mediated enhancements in NHEJ activity contribute to chemoresistance in HCC cells and patients with HCC. Targeting XLF to modulate DSB repair could enhance drug sensitivity and may be a therapeutically useful addition to conventional therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3345-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-19 /pmc/articles/PMC5437682/ /pubmed/28526069 http://dx.doi.org/10.1186/s12885-017-3345-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yang, Sitian
Wang, Xiao Qi
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title_full XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title_fullStr XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title_full_unstemmed XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title_short XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
title_sort xlf-mediated nhej activity in hepatocellular carcinoma therapy resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437682/
https://www.ncbi.nlm.nih.gov/pubmed/28526069
http://dx.doi.org/10.1186/s12885-017-3345-y
work_keys_str_mv AT yangsitian xlfmediatednhejactivityinhepatocellularcarcinomatherapyresistance
AT wangxiaoqi xlfmediatednhejactivityinhepatocellularcarcinomatherapyresistance